HealthcareServices

Gestational Trophoblastic Disease Market 2026–2030: Emerging Trends and Forecast Opportunities

February 27, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the gestational trophoblastic disease market from 2026–2035 with trusted insights from The Business Research Company

Across 2026–2030, what is the expected market valuation path of the Gestational Trophoblastic Disease Market?

The market size for gestational trophoblastic disease has experienced consistent growth over recent years. It is anticipated to increase from $2.16 billion in 2025 to $2.26 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 4.6%. The historical expansion in this market can be attributed to progress in gynecologic oncology, the widespread availability of hcg testing, the adoption of surgical treatments, a rise in awareness concerning rare pregnancy disorders, and established clinical oncology protocols.

The market for gestational trophoblastic disease is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $2.81 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.7%. This projected growth during the forecast period stems from factors such as enhanced diagnostic precision, the proliferation of oncology centers, the establishment of standardized treatment protocols, greater access to healthcare services, and a heightened emphasis on managing rare diseases. Key trends observed within the forecast period encompass advancements in HCG-based disease monitoring, a growing application of chemotherapy in GTD management, a stronger emphasis on prompt diagnosis, the broadening of specialized oncology care for women, and more effective post-treatment surveillance.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13271&type=smp

Which Drivers Are Supporting The Rise Of The Gestational Trophoblastic Disease Market?

The gestational trophoblastic disease market is anticipated to expand due to increasing rates of infertility. Infertility is defined as the inability of couples or individuals to conceive naturally after 12 months of consistent, unprotected sexual activity. The primary factors contributing to this rise in infertility are advanced maternal and paternal age, which correlate with diminished egg and sperm quality, lower fertility, and increased risks during conception. Although gestational trophoblastic disease is typically a pathological state, it can unexpectedly offer valuable insights into infertility treatments by illuminating the functions of trophoblastic tissue in implantation and hormonal regulation, thus informing strategies to enhance conception rates. For example, in April 2023, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that around 17.5% of adults, or approximately 1 in 6 individuals worldwide, experience infertility, underscoring the critical demand for better access to affordable, high-quality fertility care. Consequently, the escalating infertility rates are a key driver for the gestational trophoblastic disease market. The gestational trophoblastic disease market is projected to grow as cigarette smoking becomes more prevalent. Cigarette smoking involves igniting tobacco and inhaling the produced smoke, which carries numerous chemicals and toxins that can harm various bodily structures. This habit has the potential to damage the DNA of trophoblastic cells, which are vital for placenta formation, possibly leading to their irregular growth and division, and subsequently, gestational trophoblastic disease. An illustration of this trend is found in October 2024, when the European Respiratory Society’s (ERS), a Switzerland-based non-profit organization, published a study on youth smoking patterns showing a notable increase in smoking rates, from 22.5% of participants smoking in 2022 to 40.1% in 2024. Hence, the rising incidence of cigarette smoking is a significant factor propelling the gestational trophoblastic disease market.

What Segments Are Identified Within The Structure Of The Gestational Trophoblastic Disease Market?

The gestational trophoblastic disease market covered in this report is segmented –

1) By Type: Hydatidiform Mole, Choriocarcinoma, Placental-Site Trophoblastic Tumor, Epithelioid Trophoblastic Tumor, Other Types

2) By Treatment: Surgery, Chemotherapy, Suction Dilation And Curettage (D&C), Radiation Therapy

3) By End User: Hospital And Clinics, Diagnostic Centers, Other End Users

Subsegments:

1) By Hydatidiform Mole: Complete Hydatidiform Mole, Partial Hydatidiform Mole

2) By Choriocarcinoma: Non-Metastatic Choriocarcinoma, Metastatic Choriocarcinoma

3) By Placental-Site Trophoblastic Tumor: PSTT With Normal Placentation, PSTT With Abnormal Placentation

4) By Epithelioid Trophoblastic Tumor: Epithelioid Trophoblastic Tumor With No Evidence Of Metastasis, Epithelioid Trophoblastic Tumor With Metastasis

5) By Other Types: Trophoblastic Tumor Of Unknown Origin, Non-Gestational Trophoblastic Neoplasia

Which Leading Companies Dominate The Gestational Trophoblastic Disease Market Share?

Major companies operating in the gestational trophoblastic disease market are Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Novartis AG, Merck And Co. Inc., Sun Pharmaceutical Industries Ltd., GSK plc, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/gestational-trophoblastic-disease-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Gestational Trophoblastic Disease Market?

Asia-Pacific was the largest region in the gestational trophoblastic disease market in 2025, and is expected to be the fastest-growing region in the forecast period. The regions covered in the gestational trophoblastic disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Gestational Trophoblastic Disease Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13271&type=smp

Browse Through More Reports Similar to the Global Gestational Trophoblastic Disease Market 2026, By The Business Research Company

Human Chorionic Gonadotropin Market Report 2026

https://www.thebusinessresearchcompany.com/report/human-chorionic-gonadotropin-global-market-report

Pompe Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/pompe-disease-global-market-report

Ectopic Pregnancy Market Report 2026

https://www.thebusinessresearchcompany.com/report/ectopic-pregnancy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795